Skip to main content
. 2016 Aug 29;1(5):301–308. doi: 10.1016/j.jacbts.2016.03.012

Figure 3.

Figure 3

Cumulative Incidence Curves of Time to Progression to the Next Development Phase by Time Elapsed After Trial Start for Cardiovascular Drugs Compared With Noncardiovascular Drugs in Phase 1, 2, and 3 Trials

Cumulative incidence curves of progression to the next development phase for cardiovascular (Anatomical Therapeutic Chemical [ATC] codes B and C; shown in blue) and noncardiovascular (shown in grey) drugs in Phase 1 (A), Phase 2 (B), and Phase 3 (C) trials.